Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.

Shirish M. Gadgeel; Rimas V. Lukas; Jerome Goldschmidt; Paul Conkling; Keunchil Park; Diego Cortinovis; Filippo de Marinis; Achim Rittmeyer; Jyoti D. Patel; Joachim von Pawel; Carol O’Hear; Catherine Lai; Sylvia Hu; Marcus Ballinger; Alan Sandler; Mayank Gandhi; Lou Fehrenbacher

doi:10.1016/J.LUNGCAN.2018.12.017

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.

Shirish M. Gadgeel
, Rimas V. Lukas
, Jerome Goldschmidt
, Paul Conkling
, Keunchil Park
, Diego Cortinovis
, Filippo de Marinis
, Achim Rittmeyer
, Jyoti D. Patel
, Joachim von Pawel
, Carol O’Hear
, Catherine Lai
, Sylvia Hu
, Marcus Ballinger
, Alan Sandler
, Mayank Gandhi
, Lou Fehrenbacher

University of Michigan
Northwestern University
Blue Ridge Cancer Care
Virginia Oncology Associates, 5900 Lake Wright Drive, Norfolk, VA 23502, USA
Sungkyunkwan University
AOU San Gerardo
European Institute of Oncology
University of Göttingen
University of Chicago
Asklepios Klinik St. Georg
Genentech
Kaiser Permanente

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Lung Cancer
Volume	128
DOIs	https://doi.org/10.1016/J.LUNGCAN.2018.12.017
State	Published - Feb 1 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Radiology

Access to Document

10.1016/J.LUNGCAN.2018.12.017License: Unspecified

Cite this

Gadgeel, S. M., Lukas, R. V., Goldschmidt, J., Conkling, P., Park, K., Cortinovis, D., de Marinis, F., Rittmeyer, A., Patel, J. D., von Pawel, J., O’Hear, C., Lai, C., Hu, S., Ballinger, M., Sandler, A., Gandhi, M., & Fehrenbacher, L. (2019). Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer, 128. https://doi.org/10.1016/J.LUNGCAN.2018.12.017

Gadgeel, SM, Lukas, RV, Goldschmidt, J, Conkling, P, Park, K, Cortinovis, D, de Marinis, F, Rittmeyer, A, Patel, JD, von Pawel, J, O’Hear, C, Lai, C, Hu, S, Ballinger, M, Sandler, A, Gandhi, M & Fehrenbacher, L 2019, 'Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.', Lung Cancer, vol. 128. https://doi.org/10.1016/J.LUNGCAN.2018.12.017

@article{2c4d7d41f9d040c38881223be921cca2,

title = "Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.",

author = "Gadgeel, \{Shirish M.\} and Lukas, \{Rimas V.\} and Jerome Goldschmidt and Paul Conkling and Keunchil Park and Diego Cortinovis and \{de Marinis\}, Filippo and Achim Rittmeyer and Patel, \{Jyoti D.\} and \{von Pawel\}, Joachim and Carol O{\textquoteright}Hear and Catherine Lai and Sylvia Hu and Marcus Ballinger and Alan Sandler and Mayank Gandhi and Lou Fehrenbacher",

note = "Objectives: To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods: Patients received 1200 mg atezolizumab or 75 mg/m 2 docetaxel every 3 weeks until unacceptable toxicity, disease progression, or loss of clinical atezolizumab benefit.",

year = "2019",

month = feb,

day = "1",

doi = "10.1016/J.LUNGCAN.2018.12.017",

language = "American English",

volume = "128",

journal = "Lung Cancer",

}

TY - JOUR

T1 - Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.

AU - Gadgeel, Shirish M.

AU - Lukas, Rimas V.

AU - Goldschmidt, Jerome

AU - Conkling, Paul

AU - Park, Keunchil

AU - Cortinovis, Diego

AU - de Marinis, Filippo

AU - Rittmeyer, Achim

AU - Patel, Jyoti D.

AU - von Pawel, Joachim

AU - O’Hear, Carol

AU - Lai, Catherine

AU - Hu, Sylvia

AU - Ballinger, Marcus

AU - Sandler, Alan

AU - Gandhi, Mayank

AU - Fehrenbacher, Lou

N1 - Objectives: To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods: Patients received 1200 mg atezolizumab or 75 mg/m 2 docetaxel every 3 weeks until unacceptable toxicity, disease progression, or loss of clinical atezolizumab benefit.

PY - 2019/2/1

Y1 - 2019/2/1

UR - https://moh-it.pure.elsevier.com/en/publications/atezolizumab-in-patients-with-advanced-non-small-cell-lung-cancer

U2 - 10.1016/J.LUNGCAN.2018.12.017

DO - 10.1016/J.LUNGCAN.2018.12.017

M3 - Article

VL - 128

JO - Lung Cancer

JF - Lung Cancer

ER -

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.

Disciplines

Access to Document

Other files and links

Cite this